Sarepta Therapeutics, Inc. (NASDAQ:SRPT) Files An 8-K Results of Operations and Financial Condition

Item2.02 Results of Operations and Financial Condition.

On January10, 2017, Edward M. Kaye M.D., President, Chief
Executive Officer and Chief Medical Officer of Sarepta
Therapeutics, Inc. (the Company) disclosed certain preliminary
financial information for the year ended December 31, 2016 during
the Companys presentation at the 35th Annual J.P. Morgan
Healthcare Conference (the Conference) and in discussions with
third parties at the Conference. Specifically, the Company
disclosed that, as of December31, 2016, the Company generated
approximately $5.4 million in revenue (unaudited) from sales of
Exondys 51^TM and had
cash, cash equivalents and investments of $329.3 million
(unaudited). A copy of the slide presentation associated with
this announcement is furnished as Exhibit 99.1 and is
incorporated herein by reference.

The information in this Item 2.02 is unaudited and preliminary,
and does not present all information necessary for an
understanding of the Companys financial condition as of December
31, 2016 and its results of operations for the three months and
year ended December 31, 2016. The audit of the Companys financial
statements for the year ended December 31, 2016 is ongoing and
could result in changes to the information in this Item 2.02.

Item7.01 Regulation FD Disclosure.

The disclosure in Item2.02 above is hereby incorporated by
reference into this Item7.01.

The slides presented by Dr.Kaye at the Conference on January10,
2017 are furnished with this report as Exhibit 99.1, which is
incorporated herein by reference.

The information in this report and Exhibit 99.1 to this
report is furnished to Items 2.02 and 7.01 and shall not be
deemed filed for the purposes of Section18 of the Securities and
Exchange Act of 1934, as amended (the Exchange Act), or otherwise
subject to the liabilities of that section. It may only be
incorporated by reference in another filing under the Exchange
Act or the Securities Act of 1933, as amended, if such subsequent
filing specifically references the information furnished to
Items2.02 and 7.01 of this report.

Item9.01 Financial Statements and Exhibits.

(d) Exhibits.

About Sarepta Therapeutics, Inc. (NASDAQ:SRPT)

Sarepta Therapeutics, Inc. is a biopharmaceutical company. The Company is focused on the discovery and development of ribonucleic acid (RNA)-targeted therapeutics for the treatment of rare, infectious and other diseases. The Company operates in one segment: the development of pharmaceutical products on its own behalf or in collaboration with others. The Company, through its platform technologies, targets a range of diseases and disorders through RNA-targeted mechanisms of action. The Company is also developing therapeutics using its technology for the treatment of drug-resistant bacteria and infectious, rare and other human diseases. The Company’s lead Duchenne Muscular Dystrophy (DMD) product candidate, Eteplirsen, is an antisense phosphorodiamidate morpholino oligomer (PMO) therapeutic in Phase III clinical development for the treatment of individuals with DMD having an error in the gene coding for dystrophin that is amenable to skipping exon 51.

Sarepta Therapeutics, Inc. (NASDAQ:SRPT) Recent Trading Information

Sarepta Therapeutics, Inc. (NASDAQ:SRPT) closed its last trading session up +6.63 at 37.89 with 14,830,412 shares trading hands.